The Biden administration on Wednesday announced an extension of the pause on federal student loan payments through May 1 amid a surge of COVID-19 cases nationwide due to the omicron variant.
Continue reading “Biden Extends Moratorium On Federal Student Loan Payments Until May”Biden Signs Bill Giving Capitol Police Unilateral Authority To Request National Guard Assistance
President Biden on Wednesday signed into law a bill that would give the chief of the Capitol Police unilateral authority to request support from the National Guard. The bill easily passed both the House and Senate.
Continue reading “Biden Signs Bill Giving Capitol Police Unilateral Authority To Request National Guard Assistance”Gleeful McConnell Keeps Trying To Woo Manchin Into Joining GOP After BBB Blowup
Senate Minority Leader Mitch McConnell (R-KY) is trying to coax Sen. Joe Manchin (D-WV) into ditching the Democratic Party after the West Virginia lawmaker tanked President Joe Biden’s Build Back Better plan on Sunday.
Continue reading “Gleeful McConnell Keeps Trying To Woo Manchin Into Joining GOP After BBB Blowup”A Scientist Created A Rapid Test Just Weeks Into the Pandemic. Here’s Why You Still Can’t Get It.
This story first appeared at ProPublica. ProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter to receive stories like this one in your inbox.
When COVID-19 started sweeping across America in the spring of 2020, Irene Bosch knew she was in a unique position to help.
The Harvard-trained scientist had just developed quick, inexpensive tests for several tropical diseases, and her method could be adapted for the novel coronavirus. So Bosch and the company she had co-founded two years earlier seemed well-suited to address an enormous testing shortage.
E25Bio — named after the massive red brick building at MIT that houses the lab where Bosch worked — already had support from the National Institutes of Health, along with a consortium of investors led by MIT.
Within a few weeks, Bosch and her colleagues had a test that would detect coronavirus in 15 minutes and produce a red line on a little chemical strip. The factory where they were planning to make tests for dengue fever could quickly retool to produce at least 100,000 COVID-19 tests per week, she said, priced at less than $10 apiece, or cheaper at a higher scale.
Bosch’s prototype attracted a top Silicon Valley venture capital firm, which pitched in $2 million.
“We are excited about what E25Bio is capable of shipping in a short amount of time: a test that is significantly cheaper, more affordable, and available at-home,” said firm founder Vinod Khosla. (Disclosure: Khosla’s daughter Anu Khosla is on ProPublica’s board.)
On March 21 — when the U.S. had recorded only a few hundred COVID-19 deaths — Bosch submitted the test for emergency authorization, a process the Food and Drug Administration uses to expedite tests and treatments.
A green light from the FDA could have made a big difference for the many Americans who were then frantically trying to find doctors to swab their noses, with results, if they were lucky, coming back only days later.
But the go-ahead never came.
In the months that followed, Bosch responded to repeated requests from FDA reviewers for data and studies. When the agency finally put out guidance that summer about the performance over-the-counter home tests needed to meet, officials required that such tests be nearly as sensitive as the lab tests used to definitively determine whether a patient has COVID-19.
That standard proved difficult to meet. Rapid tests are usually sensitive enough to detect viral antigens when someone has enough of them to be able to spread the disease. Such tests are not as good at picking up cases in either earlier or later stages of infection, when viral loads are lower.
Bosch’s tests missed the FDA’s high bar. It wasn’t until the spring of 2021 that much larger companies were able to design similar tests — relatively inexpensive, over-the-counter rapid tests — that the agency found acceptable.
“You could have antigen tests saving lives since the beginning of the pandemic,” said Bosch, sitting in her lab at MIT. “That’s the sad story.”
As ProPublica recently detailed, many companies with at-home tests have been stymied by an FDA review process that has flummoxed experts and even caused one agency reviewer to quit in frustration.
While E25Bio’s test didn’t catch quite as many cases as those now on the market, it could have been used to catch superspreaders, with warnings that a negative result wouldn’t rule out infection. Experts told us that the test could have been a vital public health tool had it been produced in the millions in 2020 just as COVID-19 was racing across the country undetected.
“Since we didn’t have other options, it would have been a very good test,” said Michael Mina, an epidemiologist who followed E25Bio’s early progress. “If we were going to war, and somebody was invading us, and we had a bunch of revolver pistols, and we didn’t yet have the shipment of machine guns, hell yeah, you’re going to pick up the revolver pistol. You do what you can when you need to in an emergency.”
Three other experts reviewed Bosch’s submissions at ProPublica’s request and agreed that her test approached what is now considered acceptable for over-the-counter tests.
Mina and others have been calling for an embrace of rapid testing since the pandemic’s early days, saying that tests should be ubiquitous and cheap enough that people could stock them in their medicine cabinet, like aspirin or Band-Aids. Althoughnot a panacea, rapid tests can slow the spread of COVID-19 when used repeatedly and when the infected follow instructions to isolate,manystudiessuggest.
After not showing urgency on the issue for much of the past year, the Biden administration has moved recently to boost production and lower prices. Facing a huge new wave of cases and an increasing outcry about shortages of tests, Biden announced Tuesday that 500 million more at-home tests would be distributed by mail, starting in January.
David Paltiel, a professor at the Yale School of Public Health, said a significant part of the problem is that the FDA created a detailed roadmap for tests that give patients a close-to-definitive answer on whether they have COVID-19, but never created a separate framework for rapid tests that serve a different purpose: helping people get frequent, fast evidence of whether they may be contagious.
“The former are tests of infection; the latter are tests of infectiousness,” Paltiel said. “They both share the same regulatory pathway — a pathway that was designed with diagnostic testing in mind and is littered with requirements that make no sense for the purpose they serve.”
He added, “It’s an outrage that rapid tests aren’t dirt cheap and plentiful on grocery store shelves.”
The FDA declined to comment on individual test submissions, but said in a statement that it has worked to authorize “accurate and reliable” home tests since the beginning of the pandemic.
“Unfortunately, many submissions the FDA has received for home tests include incomplete or poor data, and it is the FDA’s responsibility to protect the public health by declining to authorize poorly performing tests or those without complete data,” the agency said. “We have also worked interactively with many developers to resolve concerns when data was incomplete or unclear, or to find solutions to issues that arose during review. If the FDA received a home test that the data and science supported in early-to-mid 2020, we would have quickly authorized it.”
Bosch has since moved on to start a new venture focused on helping other test developers conduct trials that meet the FDA’s standards. This winter, she’s working with the housing authority in the high-poverty Boston suburb of Chelsea to conduct a trial using several tests that have been authorized in other countries, but not America. The goal: to demonstrate that such tests can be effective when deployed for free, in conjunction with education and outreach.
“The next thing is frequent testing for communities that need it,” Bosch said. “How do we flood the market with a $2 test that is as good as a $20? We’re doing it in Chelsea. We should be an example for the whole country.”
American medical device regulators have never been enthusiastic about letting people test themselves.
In the 1980s, the FDA banned home tests for HIV on the grounds that people who tested positive might do harm to themselves if they did not receive simultaneous counseling. In the 2010s, the agency cracked down on home genetic testing kits, concerned that people might make rash medical decisions as a result.
But the FDA wasn’t an obstacle to Bosch’s work on tropical diseases, since the tests were mostly needed in places like the Brazilian Amazon, where infected mosquitoes are hard to escape. The National Institutes of Health thought Bosch’s tests had enough potential to give E25Bio $1.8 million for the project.
So when the pandemic struck, the small company decided to use its expertise for the new threat. Within a few weeks, Bosch and her colleagues developed antibodies that could detect the presence of proteins attached to the new coronavirus.
In her previous work, Bosch had found that tests of this type could be validated in the lab, so she ordered up some samples of the SARS-CoV-2 virus and ran two different types of antigen tests on them. She found that both worked fairly well, and packaged up all her evidence and sent it to the FDA, with little guidance on what would pass muster.
Shortly after, an FDA reviewer told her she’d need to conduct a clinical trial, which would take months. “My first huge surprise was when they said, ‘Nope, none of your validations are going to pass for an EUA,’” Bosch said.
The next challenge was that the accuracy of antigen tests would be measured by how they compared to a different type of diagnostic: the polymerase chain reaction, or PCR, test, which is considered the “gold standard” for finding coronaviruses. Many see that as an unproductive comparison, given the fact that PCR detects remnants of the virus, which may persist for many days after the infection ceases to be a threat.
“When you’re PCR testing, you’re testing for the presence of viral genetic material,” said Hannah Mamuszka, the CEO of Alva10, a company that helps diagnostics manufacturers prove their value for insurers. “When you’re antigen testing you’re testing for presence of a protein on the surface of the virus,” she said. “Those are obviously not the same thing. So it’s really confounding that the FDA has had such a hard time communicating what they need, and defining what a test would need to look like to be used at home.”
Nevertheless, by April 2020, E25Bio had lined up a trial with three hospitals in Florida. They found the test identified 80% of the swabs that a PCR test had shown to be positive (known as sensitivity) and 94% of the negatives (known as specificity).
The FDA wanted to see fewer false positives, even though people who test positive on an antigen test are usually advised to confirm it with a PCR. And while the overall sensitivity of E25Bio’s test was lower than other tests would later demonstrate, it measured 100% for people with higher viral loads — those most likely to be infectious.
Bosch was in frequent contact with her assigned reviewer at the FDA, and even talked to Tim Stenzel, the head of the agency’s office that vets diagnostic tests. The Bill & Melinda Gates Foundation gave E25Bio another $500,000 to continue research and development.
But at the end of July 2020, the FDA came out with a template that laid out the expectation that tests available for home use without a prescription would reach 90% overall sensitivity — that is, antigen tests would pick up nine out of ten positive tests that a PCR identified. Bosch knew her tests couldn’t meet that standard. And without an EUA for home use, they wouldn’t be able to serve their intended function.
Already, plenty of models had illustrated the importance of frequent testing, including one co-authored last year by Yale’s Paltiel with Rochelle Walensky, now head of the Centers for Disease Control and Prevention. In September 2020, as chief of infectious diseases at Massachusetts General Hospital, Walensky argued that antigen tests were actually most useful for pinpointing people at their most infectious.
In fact, the utility of that approach was being tested at Bosch’s own former workplace. Beginning in the late summer of 2020, a coworking lab space in Cambridge where E25Bio had launched started a trial with 257 of its users who agreed to take both the antigen rapid test at home and a PCR test twice a week. (This was also closer to a home use scenario than the Florida hospitals study, in which COVID-19 was more prevalent and tests were administered by medical professionals.)
A peer-reviewed paper based on the results showed overall sensitivity of 79%, and that the rapid test picked up nearly all of the positives later detected by a PCR in the first few days after symptoms appeared, allowing infected people to stay out of the office as soon as they knew.
But the FDA does not consider test performance data broken out by how much virus the subjects have in their systems, saying the typical method for measuring it is inconsistent. Nor did the agency initially authorize tests on the condition that they be sold in packs of more than one, with instructions to use them sequentially to catch any fast-moving infections.
Bosch wasn’t the only one to be tripped up by the new standard. In mid-September 2020, Stenzel said on his weekly town hall call with test developers that his office had received zero applications for home use tests, a month and a half after putting out the template, despite his insistence that the agency was willing to be “flexible.”
Meanwhile, a $666 million NIH program to accelerate the approval and production of new COVID-19 tests funded mostly PCR tests in 2020.
The antigen tests that did make it into the NIH program in the first threefundingrounds — including one made by Quidel, a public company that multiplied its profits by tenfold in 2020 over the previous year — generally had to be processed in labs or required expensive analyzers.
One of few simple antigen tests to win government support, made by Maxim Biomedical, still hasn’t submitted an EUA application, according to chief operating officer Jonathan Maa. Another grantee, Ellume, was authorized for nonprescription home use in December 2020. But it took months to go into widespread production, and still costs $39, if you can find it.
Toward the end of October 2020, Bosch received a 48-hour ultimatum from the FDA for a response to a request for additional data. She had answers to the agency’s questions, but didn’t quite make that deadline.
By the time she replied, the FDA had already closed her application. “You call and they say, ‘Oh sorry, the clock started and we can’t stop it,’” she said.
Soon after, the company’s leadership asked her to resign. The company continues to operate, but hasn’t obtained FDA authorization for any tests. “As we commercialize our COVID-19 rapid tests internationally, we are also focused on developing the next generation of rapid tests for consumer diagnostics,” an E25Bio spokesperson said, while declining to comment on Bosch’s departure or its current product pipeline.
“All our life, day in and day out, went to make antigen tests,” Bosch said. “It was tragic, because it was all because the FDA decided to be so harsh in their responses that investors said, ‘Oh, there’s no way she will pull it out.’”
E25Bio’s travails with the FDA didn’t stop Bosch from putting her expertise to use.
In early 2021, she started talking to the city of Chelsea about running a trial that could show how rapid antigen testing — even with the types of tests that the FDA had rejected — could be rolled out in a high-risk community. In the spring, when infection rates in Chelsea were among the highest in the nation, many residents had had a difficult time accessing PCR tests, because the places administering them often dissuaded immigrants by requiring identification.
Chelsea officials agreed, and Bosch secured donations of tests from five manufacturers that had been authorized in Britain, Germany, India or Korea, but none yet in the U.S. (They can still be used here for research purposes.) She said she has validated them in her lab and found them to be about as accurate as BinaxNOW, the FDA-authorized home test made by medical device giant Abbott Laboratories.
“If they have a budget for next year to do frequent testing, this will be an accomplishment,” Bosch said. “I wanted to show to the world that an experimental device is just as good as any other already-approved FDA test.”
So for the past few months, Bosch has canvassed three buildings owned by the local housing authority. Bosch, who is from Venezuela, puts on salsa music and explains in Spanish how the program will work.
The trial began in earnest last week, with study administrators walking newly enrolled subjects through using the tests. In a building reserved for elderly and disabled people, residents entered with walkers and in flip-flops to learn how to swab their noses, put the swabs in a vial of solution, squeeze a few drops onto a pad and wait anxiously for the single line to appear that would indicate a negative result.
Most were able to take a picture of the results with their phones and upload them using a special app, which they’ll continue to do in their homes each week.
The FDA frowns upon this kind of instruction in trials for at-home tests — users are supposed to be able to execute the test without training. But in reality, many need support.
For the nonprofit that helped launch the effort, the Center of Complex Interventions, the important part is demonstrating that rapid tests can work when used as part of a coordinated testing regime to address specific situations: right before people gather indoors or after an exposure to an infected person, for anyone in a high-risk job, for people in crowded living situations, or for those who have health risk factors. People in all of those situations are concentrated in Chelsea’s housing authority buildings.
“It’s a lot different than saying, ‘Let’s roll it out to everybody,’” said Karthik Dinakar, who is leading the project. “It all has to be connected in a way that makes people feel like they’re participating. The goal for us is to make the community safer, and also shift the mindset to a new equilibrium.”
Joshua Sharfstein, a vice dean at Johns Hopkins University’s Bloomberg School of Public Health who used to be principal deputy commissioner of the FDA, said that rapid tests could have been authorized earlier with these kinds of protocols in mind.
“There was no testing strategy,” Sharfstein said, outlining the opportunity that America missed to use a variety of tests for the purposes to which they were best suited. “What they could have done is to say, ‘Here are the six uses of tests. You’re sick, you’re exposed, you’re trying to maintain people on a campus. What’s the performance of test that you would need?’
“Just think how amazingly helpful that would be,” he finished, wistfully.
Meanwhile, the CDC and NIH have been studying similar programs in a handful of communities using Quidel’s at-home test. Governors have been catching on to the utility of rapid tests too. Last week, the state of Massachusetts bought millions of rapid test kits made by iHealth laboratories. The company’s chief operating officer, Jack Feng, told National Public Radio that the price was higher in the U.S. because of the expense of clinical trials that aren’t required elsewhere.
And since rejecting Bosch’s submissions, the FDA has been coming around to her way of thinking. In March, the agency published a template for tests that would be used serially and sold in packages of two or more, allowing the kind of frequent testing she had advocated for. And last month, it published a new template that lowered the sensitivity standard for over-the-counter tests to 80%.
Bosch had tests a year and a half ago that missed that bar by 1%.
One Shot to Rule Them All
Back on December 9th we discussed the quickening hunt for a Sarbecovirus vaccine. This is basically a vaccine that wouldn’t target this or that variant but the whole class of SARS-related coronaviruses. Basically the idea is you go upstream in the viral family tree to cover the whole class of contagions and potential future ones. Last night Army researchers at Walter Reed Army Institute of Research say they’ve developed just such a vaccine, or at least one that cover all current and potential variants of COVID19.
Continue reading “One Shot to Rule Them All”More And More Trump Goons Desperately Try To Sue Their Way Out Of Jan. 6 Scrutiny
A lot of things happened. Here are some of the things.
Welcome To The Club, Flynn
Convicted ex-Trump adviser Michael Flynn filed a lawsuit against the House Jan. 6 select committee yesterday, claiming that its subpoenas for his electronic records and testimony could violate his Fifth Amendment right against self-incrimination in other investigations he’s tied to (like the reported federal probe into Sidney Powell’s Defending the Republic PAC).
- These are the other top Trump foot soldiers who’ve sued the committee to stonewall its investigation in case you’re having trouble keeping track (I can’t blame you):
- Former White House Chief of Staff Mark Meadows
- Trump legal adviser John Eastman
- Far-right conspiracy theoriest Alex Jones
- “Stop the Steal” leader Ali Alexander
- Cleta Mitchell, the election lawyer who was on Trump’s infamous call when he tried to pressure Georgia officials to “find” votes for him to steal the state from Biden
Georgia County Trying To Shut Down All But One Polling Site
Georgia’s Lincoln County Board of Elections is aiming to close six of the county’s seven polling places ahead of next year’s elections to supposedly make voting “easier and more accessible,” the board claims.
- Some county residents live as far as 23 miles away from the county seat, a former county school board member told the Augusta Chronicle.
- The board’s efforts were made possible by Georgia Republicans’ voter suppression legislation. Under that legislation–the chief sponsor of which was a GOP senator who represents Lincoln County– the county board of elections was disbanded and replaced with new appointees.
- The board was slated to vote on the change last week but seemed to lack a quorum, according to the Augusta Chronicle.
Dem Senators Hold Private Call With Manchin On BBB
During Democratic senators’ virtual call on Tuesday night, Sen. Joe Manchin (D-WV) told his colleagues that he was still open to negotiations on Build Back Better despite still having issues with it, according to CNN.
- Manchin reiterated his complaints about BBB in the beginning of the call but mostly listened to his colleagues speak during the discussion, CBS News reports.
- Senate Majority Leader Chuck Schumer (D-NY) reportedly said on the call that the chamber would hold a vote on BBB in January, per CNN.
Manchin’s BBB Bombshell Renews GOPers’ Defection Calls
Republican senators like Senate Minority Leader Mitch McConnell (R-KY) and Sen. John Cornyn (R-TX), who are utterly delighted with Manchin after he struck a major blow to BBB, are inspired to keep wooing the West Virginia senator over to their side of the aisle.
- Manchin would be “more comfortable” in the GOP, McConnell argued on Tuesday.
- Cornyn texted Manchin yesterday telling him “Joe, if they don’t want you we do,” the Texas Republican said.
FDA To Greenlight COVID Pills
The Food and Drug Administration is expected to approve pills to treat COVID-19 by Pfizer and Merck as soon as this week, according to Bloomberg. The pills are for higher-risk patients who would take the medicine at home over the course of several days.
House GOPers Prep Revenge Probes
Get ready for Benghazi on crack come 2023 if Republicans take control of the House in the midterms as predicted: House Minority Leader Kevin McCarthy (R-CA) is already mapping out his plans for various culture-war based investigations into the Biden administration. Subjects include the withdrawal from Afghanistan, Attorney General Merrick Garland’s crackdown on threats against school board members and (of course) the southern border.
Must Read
“The protests that defined 2021: Coronavirus, climate change and the Capitol riot” – The Washington Post
“The Future Is Not Only Useless, It’s Expensive” – Gawker
2021 US Population Growth Rate Slower Than Any Other Year
At just 0.1 percent, 2021 saw the slowest population growth rate in American history, according to the Census Bureau.
Top GOP Senator Mulls Potential Retirement Amid Trump’s Grip On Party
Senate Minority Whip John Thune (R-SD) is considering leaving Congress in 2022 due to family reasons and also because of Trump’s control over the GOP, the New York Times reports.
Vaccinated Gosar Urges Anti-Vaxxers To Stay Unvaxxed
Far-right Rep. Paul Gosar (R-AZ) encouraged an anti-vaccine group to “stay the course” in a video with anti-vaxx activist Ethan Schmidt yesterday, even though the Republican told the Arizona Mirror in December last year that he was waiting in line for the vaccine, and his office told CNN in May that the congressman had gotten the vaccine.
Watching politicians peddle life-threatening lies to their constituents. What a time to be alive.
DC Press Gonna DC Press
Dear readers, I solemnly swear that no Morning Memo will ever be this awkward:
Do you like Morning Memo? Let us know!
Where Things Stand: One Bright Spot For Biden As 2021 Draws To A Grim End
Sen. Joe Manchin (D-WV) has effectively doomed President Biden’s hopes of passing his most meaningful legislative package this year. Things aren’t looking any better for Democratic efforts on voting rights (also largely Manchin’s fault). While the administration has made significant advances in getting the country vaccinated this year, Omicron has brought pandemic-ending progress to a standstill for now.
But the Biden administration, with the help of Senate Majority Leader Chuck Schumer (D-NY), has quietly made some progress on one major pillar of Biden’s presidency: confirming judges.
Continue reading “Where Things Stand: One Bright Spot For Biden As 2021 Draws To A Grim End”The Sausage Making: Biden Says He And Manchin ‘Are Going To Get Something Done’
Your intermittent briefing on negotiations over the reconciliation bill.
President Joe Biden told reporters Tuesday that he still thinks “there’s a possibility of getting Build Back Better done.”
Continue reading “The Sausage Making: Biden Says He And Manchin ‘Are Going To Get Something Done’”Jan. 6 Committee Will Consider ‘Other Tools’ To Get Info After GOP Rep Refuses To Cooperate
The House Jan. 6 Committee said Tuesday that it would consider using “other tools” to collect information after Rep. Scott Perry (R-PA) rejected the committee’s request for cooperation.
Continue reading “Jan. 6 Committee Will Consider ‘Other Tools’ To Get Info After GOP Rep Refuses To Cooperate”How Black Communities Become ‘Sacrifice Zones’ for Industrial Air Pollution
This story first appeared at ProPublica and Mountain State Spotlight. ProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter to receive stories like this one in your inbox.
Every time Pam Nixon drives along Interstate 64, she sees the Union Carbide plant. Wedged between a green hillside and the Kanawha River, the sprawling facility has helped define West Virginia’s “Chemical Valley” for the better part of a century, its smokestacks belching gray plumes and fishy odors into the town of Institute, population 1,400. To many West Virginians, the plant is a source of pride — it was a key maker of synthetic rubber in World War II — and a source of hundreds of jobs. But to Nixon and others in Institute’s largely Black community, it has meant something else: pollution. The plant reminds Nixon of leaks, fires, explosions — dangers she’s dedicated most of her adult life to trying to stop.
Now, on a warm September evening, the 69-year-old retiree was at it again.
Surrounded by files, documents and reports in her cluttered home office, she turned on her computer around 6 p.m. and logged on to Zoom. On the screen were U.S. Environmental Protection Agency officials from Washington, D.C., and state regulators from the capital, Charleston. She had spent weeks calling and emailing residents to convince people to attend. Her goal: show officials that her community was watching them. “You have to be persistent,” she said. Nixon watched approvingly as the audience grew to nearly 300.
The threat this time: ethylene oxide, a cancer-causing chemical that facilities like the Union Carbide plant, now owned by Dow Chemical, make and that helps produce a huge variety of products, including antifreeze, pesticides and sterilizing agents for medical tools. The regulators, their Zoom backgrounds set to photos of pristine pine forests and green fields, shared a map of the area, a short drive west from Charleston. Institute, one of just two majority-Black communities in the state, is home to West Virginia State University, a historically Black college whose alumni include Katherine Johnson, the NASA mathematician made famous by the film “Hidden Figures,” and Earl Lloyd, the first Black player in the NBA. Blocks on the map were shaded green, yellow or red, from lowest to highest cancer risk. Much of Institute was bright red.
Institute is representative of Black communities across the country that bear a disproportionate health burden from industrial pollution. On average, the level of cancer risk from industrial air pollution in majority-Black census tracts is more than double that of majority-white tracts, according to an analysis by ProPublica, which examined five years of emissions data. That finding builds on decades of evidence demonstrating that pollution is segregated, with residents of so-called fence-line communities — neighborhoods that border industrial plants — breathing dirtier air than people in more affluent communities farther away from facilities.
The disparity, experts say, stems from a variety of structural imbalances, including racist real estate practices like redlining and decades of land use and zoning decisions made by elected officials, government regulators and corporate executives living outside these communities. That means that these areas, many of which are low-income, also lack the access that wealthier areas have to critical resources, like health care and education, and face poorer economic prospects.
All of the concentrated industrial activity in these so-called “sacrifice zones” doesn’t just sicken the residents who happen to live nearby. It can also cause property values to plummet, trapping neighborhoods in a vicious cycle of disinvestment. In Institute, for example, West Virginia State, starved of state funding for years, has struggled to expand and recruit students. The school is now suing Dow Chemical, the plant’s owner, and arguing that contaminated groundwater beneath the campus inhibits the school’s development plans and harms its national reputation. Dow has sought to dismiss the case, and an appeals court is considering whether the matter belongs in state or federal court.
Many of the 1,000 hot spots of cancer-causing air identified by ProPublica are located in the South, which is home to more than half of America’s Black population. “None of this is an accident,” said Monica Unseld, a public health expert and environmental justice advocate in Louisville, Kentucky. “It is sustained by policymakers. It still goes back to we Black people are not seen as fully human.”
To be sure, white communities face elevated cancer risks too, including the largely white neighborhoods across the river from the Union Carbide plant. But Institute is one of just two majority-Black census tracts in a state that’s 94 percent white, and the town contains one of the most dangerous facilities in the state and the nation. Of the more than 7,600 facilities across the country that increased the surrounding communities’ excess estimated cancer risks — that is, the risk from industrial pollution on top of any other risks people already face — the Institute plant ranked 17th, according to ProPublica’s analysis. The area within and around the plant fence line has an excess cancer risk from industrial air pollution of 1 in 280, or 36 times the level the EPA considers acceptable. Last year, a state health department investigation found communities living downwind of the chemical plants in Institute and South Charleston are seeing a spike in ethylene oxide-related cancers but cautioned that the findings were “not conclusive.”
Dow Chemical did not respond to multiple requests for comment. A company spokesperson told the Charleston Gazette-Mail this year that its plant emissions were safe, but that it was dedicated to further reducing them.
Government officials at the Zoom meeting that September night asked the crowd not to panic. Cancer risks are complicated, they said, and the plants are working to reduce their emissions. The officials also promised that regulatory agencies were considering new rules to protect public health. Nixon nodded as she listened: She had heard all of this before.
When residents got a chance to speak, Scott James piped up. The mayor of St. Albans, where many plant workers live, warned that when environmental regulators come to town, it threatens the region’s economic health. “I’m scared to death it’s going to end more jobs in the Kanawha Valley,” said James, who is white. “That’s what I’m scared of.”
But as they had so many times before, Nixon and other Black attendees pressed the regulators about protecting Institute. “I want to make sure that that is on the record that I have huge concerns about this particular community, which is largely African American. Historically African American,” said Kathy Ferguson, a local activist and community leader. “I feel like we’ve been crying out for help for so long and fallen on deaf ears.”
Throughout West Virginia’s history, political power has been concentrated in heavy industries — coal, chemical manufacturing, natural gas, steel — in part because of the jobs that flow from them. Those sectors also are among the largest sources of campaign contributions for those running for political office. Elected officials and the regulatory agencies they control face pressures to not be too tough, or even appear to be too tough, and worker safety and environmental protection often suffer as a result. Chemical plants are simply part of the landscape.
Nixon moved to Institute in 1979, just after getting married. It was an easy decision to make her home in the Black community that had formed around the college, where her husband worked as a groundskeeper. His family also owned property in town, and the newlyweds built a home not far from the campus. She worked as a medical lab technician at a nearby hospital.
At first, the Union Carbide plant was as remarkable to her as a gallon of milk. She had grown up across the river, in the east end of Charleston, not far from the water — close enough that her neighborhood caught the smell when the occasional chemical spill caused a fish kill. “They just belched out all of these chemicals into the air and water,” Nixon said. “And people would say, ‘What’s that smell? Well, it smells like money.’”
The area’s gradual transformation into Chemical Valley upended the original vision for Institute. The town began as a small Black community founded by formerly enslaved people who had been freed by a rich, white plantation owner upon his death in 1865. The journal West Virginia History has described Institute at that time as “one of the few places freed slaves could live in peace” in the state.
It later became home to the West Virginia Colored Institute — created because the federal government had ordered states to either eliminate race-based entrance policies or create separate schools for Black students. West Virginia’s leaders chose the latter, but, as they scouted locations along the Kanawha River, they encountered hostile crowds, until they reached Institute.
The town grew up around the school, becoming a center of Black life in an overwhelmingly white state. The city of Charleston later built the region’s first commercial airport, Wertz airfield, which would soon serve as a training ground for some of the nation’s first African American pilots, the forerunners of the famed Tuskegee Airmen.
As World War II heated up, though, government officials had other ideas for the land. Concerned about a potential shortage of rubber for the military effort, they turned to Union Carbide Corporation, which was already operating chemical plants up and down the Kanawha River valley.
The company built a new plant on the site of the Wertz airport, making butadiene, the key to synthetic rubber. Carbide’s official history said the spot was “the only reasonably flat ground nearby.” After the war, Carbide developed the operation into a 400-acre manufacturing complex, which, over the years, has had several other owners, including Rhone-Poulenc and Bayer CropScience. Over time, the Kanawha Valley emerged as a home to a large collection of chemical plants, lured in part by the region’s salt deposits, river access and cheap coal for power. The plants had now-familiar names like DuPont and Monsanto, and they provided thousands of jobs, helping to usher in a middle-class life for many in the region. The national media marveled at the valley’s “chemical magic,” as The Saturday Evening Post put it.
But for the residents of Institute, the picture was far dimmer. For years, Carbide “hired Blacks in only the low-paying menial jobs, while whites were hired into better-paying positions,” according to sociologist Robert Bullard, who interviewed longtime residents there for his landmark 1990 study of environmental justice, “Dumping in Dixie.” Local residents, he wrote, made up less than 10% of the plant’s workforce.
Meanwhile, they lived under a steady stream of pollution, leaks and explosions.
Newspaper articles from 1954, for example, describe a huge explosion at the Institute plant. “58 Hurt As Carbide Blast Rocks Valley,” blared the headline across the top of the Charleston Gazette’s front page. One resident told the paper, “All I remember seeing was a big fire.” Another man, who was working at a gas station across the river, was injured when glass rained down on him from windows shattered by the explosion.
Michael Gerrard, who is white, grew up in Charleston during this period. He went on to become a professor of environmental law at Columbia University. While in college, Gerrard researched the local chemical industry for a paper that he titled “The Politics of Air Pollution in the Kanawha Valley: A Study of Absentee Ownership.”
Gerrard noted that plant managers mostly lived in one upscale neighborhood of Charleston, “far away from the sights and smells” of Carbide or other chemical companies.
But the people in Institute, like residents of other fence-line communities across the country, had little knowledge of the chemicals next door; companies were not required to disclose what they used or stored, let alone what they pumped into the air or water. “Nobody knew what was there or what was really coming out,” Nixon said.
It took a chemical disaster halfway around the world for that to change. In 1984, a Union Carbide plant in Bhopal, India, leaked a chemical called methyl isocyanate, or MIC. Thousands of poor families living nearby woke up coughing and choking, the toxic gas burning their lungs and eyes. Estimates of the death toll vary, but range as high as 15,000. In Institute, Nixon was cooking dinner when she heard about the accident on the evening news. Her heart sank. “When I heard the acronym MIC, I remembered seeing those letters on the sides of empty 18-wheel truck tankers as they passed my home,” Nixon said.
Carbide had added a methyl isocyanate unit in Institute in the late 1960s. Made from phosgene, a toxic gas used as a chemical weapon in World War I, MIC was a key ingredient in new pesticides. The facility was the only plant in the U.S. that stored large quantities of the chemical, and within hours of the Bhopal leak, Carbide shut down its production.
The company then spent $5 million on a project that it said made “a safe unit safer.” Carbide also invited local civic leaders to tour the facility and hired a public relations firm to push the idea that its methyl isocyanate unit wasn’t a danger to the community. “We’ve looked at this facility with a fine-tooth comb,” company spokesman Thad Epps said at a press conference just before production of the dangerous chemical resumed on May 5, 1985. “We know the whole world is watching what we’re doing.”
Three months later, on a hot Sunday morning, a firetruck rolled down Nixon’s street. “Stay inside,” blared the warning from a loudspeaker. The voice announced that there had been a chemical leak at Carbide. Nixon and her family were getting ready for church as officials instructed residents to turn off their air conditioners. “I’m thinking, ‘Turn off your air conditioner? It’s August,’” Nixon recalled. She and her husband ignored the shelter-in-place warnings and rushed to their church in South Charleston, farther from the plant. Then they went to her mom’s house, a little farther away, before coming home that afternoon.
Within a few hours, though, Nixon’s throat was scratchy. She had a cough. “It was beginning to burn down my throat,” Nixon recalled. Eventually, her husband took her to a local emergency clinic. In all, 135 residents had sought medical help that day for eye, throat and lung irritation.
Her son, Eric, had been away when the leak happened, celebrating his 16th birthday with family friends. “I called and told them to keep him because we had just had a major leak,” Nixon recalled. “Of course, Eric said that he was coming home because if we were going to die, we were all going to die together.”
If Bhopal ignited environmental activism within Institute, the leak in West Virginia supercharged it. And West Virginia State became the center of the emerging movement. Leading the charge was Kathy Ferguson’s father, Warne, who had grown up in Institute and attended West Virginia State before going off to New York to teach in Harlem. He had returned home to run two youth programs at the college, and he soon joined with faculty and other residents, including Nixon, to form a new group to pressure Carbide to get rid of its huge stockpile of the deadly chemical. They called it People Concerned About MIC.
“We would smell things and we would call” the plant and state regulators, Kathy Ferguson recalled. “Smell something, say something. That was the motto in our house.”
As the residents of Institute were beginning to reckon with the threats posed by their industrial neighbor, the country was becoming increasingly aware of the disproportionate risks that communities of color were facing from polluters.
In 1982, the dumping of contaminated soil in the predominantly Black community of Afton, North Carolina, prompted a landmark U.S. General Accounting Office report, which examined four hazardous waste disposal sites and found that three of them were in mostly Black communities. More activism and studies followed, including the watershed “Toxic Wastes and Race in the United States.” Published in 1986 by the United Church of Christ’s Commission for Racial Justice, it found “an inordinate concentration” of toxic waste sites in Black and Hispanic communities. “The possibility that these patterns resulted from chance is virtually impossible,” the paper said.
In Houston, Bullard had already finished his own study, finding that garbage disposal sites in that city were almost all in Black neighborhoods. Bullard was continuing his research when he read about Institute in the national media. “A lot of people didn’t even know there were Black folks in West Virginia,” Bullard recalled in a recent interview. “So I had to go to West Virginia.”
When he did, Bullard found a pattern that matched what he’d seen in the other communities he was studying: Black residents lived in close proximity to polluting facilities but received few of the economic benefits of those plants.
For many years, people inside the EPA did not seem to grasp that “the impacts communities said were happening were even happening,” according to Mustafa Ali, a vice president of the National Wildlife Federation and a former senior environmental justice adviser at the EPA. That dynamic started to change as the mountains of evidence from scholars like Bullard demonstrated time and again that environmental regulations were failing to protect communities of color. But the EPA did little to address the problem.
In Washington, elected officials pursued legislation that, while giving citizens more information, ultimately placed the onus for forcing change on activists instead of regulators. After the Institute leak, for example, then-U.S. Rep. Bob Wise, a Democrat who represented the Kanawha Valley, helped craft the Emergency Planning and Community Right-to-Know Act, or EPCRA, the nation’s first chemical right-to-know law. He told the media at the time that he had gone door to door to talk to residents after the accident. “What I was hearing was that people were smelling the gas or seeing it before they ever had a warning,” he said. Carbide later acknowledged that company officials waited 20 minutes before warning residents of the leak, potentially wasting a critical window in which the plant’s neighbors and emergency responders could react.
Passed by Congress and signed into law by President Ronald Reagan in 1986, the EPCRA did not set up new safety regulations, nor did it require enforcement actions, like independent environmental audits or ingredient switching, that would force companies to use less toxic chemicals at their plants. Instead, the measure gave residents and first responders new tools to better understand the dangers in their communities.
The law required companies to help local emergency responders plan for accidents and “immediately” notify authorities about leaks, but it didn’t specify what “immediately” meant. The law also mandated that companies disclose their chemical inventories and emissions, but it didn’t cover all chemicals and it exempted smaller leaks. Moreover, under the law, all numbers are self-reported by the companies and not always made public in ways that are easy for people to access or understand.
In a recent interview, Wise acknowledged the law was a compromise. “There is constant tension that always exists,” Wise said. “‘Do we have a safety problem we have to do something about?’ and ‘Are we going to drive jobs out of the Kanawha Valley?’”
Just a week after the Institute leak in 1985, more than 400 people paraded through South Charleston, where the company owned another sprawling plant, in support of Union Carbide. “Hey, hey, what do you say? We say Carbide all the way,” marchers chanted, as shown in the 1991 Appalshop documentary “Chemical Valley.”
Many of the marchers worked at Carbide or had family members who did. “This is a Carbide town,” then-South Charleston Mayor Richie Robb said at the march. “There’s not a household in this town that doesn’t have a member of the family or a relative working for Carbide.”
In a front-page account of the march, the Sunday Gazette-Mail noted one sign that said, “Almost Heaven Would be Almost Hell Without Carbide.” Another said, “We Love Union Carbide,” and featured a heart with dollar signs, the paper said.
During a public appearance in the valley, Warren Anderson, then Carbide’s chairman, remained defiant, warning that calls for chemical plants to take stronger safety measures would hurt the broader economy and society. “Somebody has sold a bill of goods that this is a zero-risk world,” Anderson said at the time. “In today’s environment, you couldn’t invent the pencil. It has a very sharp point. Children use it. You can stick it in your eye or your ear. I doubt that you could get the pencil introduced in the market today.”
Meanwhile, People Concerned About MIC ratcheted up the campaign against Carbide, organizing around the idea that the 1985 leak could have been worse. “None died this time, but what’s next?” said one ad for a community meeting. Nixon and others went to shareholder meetings. Environmentalists and some chemical workers joined forces, bringing survivors of the Bhopal disaster to town. But advocates ran into practical complications: While the new law had given them more information about what the plant produced, they were on their own when it came to learning about the toxicity of the complicated chemicals, keeping logs of incidents at the facility and launching letter-writing campaigns, which they did while holding down jobs, going to church and helping kids with their homework.
“It was almost like a job for me,” said Nixon, who was also working full time as a medical technician. “It takes a lot of determination and life gets in the way.”
Moreover, the residents of Institute lacked a political champion.
Institute was an unincorporated area, meaning that it had no town council, mayor or direct representatives. The most local government body was the Kanawha County Commission. In “Dumping In Dixie,” Bullard found that in fence-line communities, “government inaction reinforces a system of exploitation” and “exposes low- and middle-income Black neighborhood residents to potential health risks.”
To enhance their clout, some residents sought to incorporate Institute with two other Black communities nearby. Carbide, however, would have been the single largest taxpayer in the new town, and the company fought the effort, which failed, leaving residents little political leverage.
With each new leak and explosion — including one in August 1993 that claimed the lives of two workers — relations between the plant and the community deteriorated. At one public meeting, longtime Institute resident Donna Willis said that when she reported an odor to the plant, “They send a person over that tells me I have a gas leak,” she said. “I live on an all-electric facility. There is no gas.” Sue Davis, another longtime resident, said “The Right to Know Act is fine. The problem is, when we call the plant to know something, they say it’s nothing to know.”
Although no official was championing Institute’s cause, some hope for change came in 1998, when Nixon, by then one of the state’s higher-profile environmental activists, took a job as the environmental advocate at the West Virginia Department of Environmental Protection. The position had been created several years before, in response to complaints that state regulators were too friendly with the industries they regulated.
The new role sent Nixon to meetings around the state, where chemical companies would meet with locals. She noticed a troubling trend. Community groups in white areas got more answers, more details, more information than those in Institute, she said. The companies “saw the people in South Charleston as their peers,” Nixon said, referring to the predominantly white area. “They saw the people in Institute as a little less. I always saw that as a racial thing.”
Still, Nixon leaned into the role and scored some victories. For example, she convinced the agency’s air-quality office to more carefully examine the existing pollution burden on the coal community of Sylvester, and officials ultimately rejected a permit for a new synthetic fuels facility there. But more often than not, Nixon felt outmatched by West Virginia’s pro-industry politics: Industry lobbyists and state lawmakers made shrinking or eliminating her job a favorite pastime.
Shortly after 10:30 p.m. on Aug. 28, 2008, a fireball shot hundreds of feet into the air above the Institute plant, which at the time was owned by Bayer CropScience. A runaway chemical reaction had caused a 5,000-pound tank to explode, sending out shockwaves that were felt as far as 10 miles away. Two plant workers were killed.
As flames licked the sky, local residents and emergency responders scrambled for information. The only Bayer employee talking to them was a guard at the plant gate who said he wasn’t authorized to provide any details. “I’m only allowed to tell you that we have an emergency at the plant,” he said.
Frantic neighbors called Nixon, but even she — working as a state official and living in South Charleston — couldn’t get information. “I knew what they were feeling,” Nixon later told lawmakers. “It is like a wave that engulfs you when you hear an explosion, when you feel your home shake, when you see the smoke and the glow of the fire go up into the sky, not knowing what will happen next and fearing for the safety of your family. When you live that close to a chemical plant, you learn that every minute counts.”
Emergency personnel only gained access to the plant after high-ranking state officials threatened to have Bayer plant management arrested.
This was precisely the type of situation that the Emergency Planning and Community Right-to-Know Act was meant to prevent. But it made little difference that night. Bayer later said that its communications with emergency responders “while well intentioned, inadvertently created confusion and concern.”
Again, Washington responded, this time with a broad investigation by the U.S. Chemical Safety and Hazard Investigation Board, which found the accident could have been much worse. Projectiles could easily have hit a tank nearby that contained nearly seven tons of methyl isocyanate. “This was potentially a serious near miss, the results of which might have been catastrophic for workers, responders, and the public,” then-board Chairman John Bresland testified. A report from congressional investigators was more blunt: “Had this projectile struck the MIC tank, the consequences could have eclipsed the 1984 disaster in India.”
The board ultimately blamed the fatal explosion on a combination of poor safety practices by Bayer and a lack of comprehensive regulations and enforcement by federal, state and local authorities. Separately, the EPA and the Justice Department cited Bayer’s lack of transparency in a federal lawsuit that alleged a wide array of violations.
That case appeared to end with a 2015 settlement, and Bayer agreed to pay $975,000 in fines. But two years later, Bayer petitioned the government to modify the deal, which had included an additional pledge to complete a water pollution control project in Institute and another community; the company now wanted to buy pumper trucks and radio equipment for local fire departments instead. The EPA and DOJ signed off, over the objections of Nixon and other activists, and a federal judge approved the changes.
In response to questions from ProPublica and Mountain State Spotlight, Bayer spokesperson Susan Skiles Luke said that “we continue to feel for those affected” by the explosion and that Bayer “accepted and implemented all of the recommendations that the Chemical Safety Board made as part of the agency’s resulting investigations, and made additional, voluntary changes across its operations.”
But one wider recommendation went unaddressed: Looking to prevent future accidents, the chemical board called for officials from all levels of government to create a local safety program to police the Kanawha Valley’s chemical industry. Industry groups, however, opposed the proposal, saying it would create “additional economic burdens” on plants, and it went nowhere.
Meanwhile, in the state capitol, then-Gov. Joe Manchin was concerned. “On a night last August, here in the Kanawha Valley, the sky glowed orange after an explosion and a fire at one of our chemical plants,” he told state lawmakers in his 2009 State of the State address. “In the critical hours after the explosion, we had a lot of unanswered questions that left residents throughout the valley scared and wondering exactly what to do.” He urged lawmakers to pass a new law requiring that serious industrial accidents be reported to the state within 15 minutes, closing the EPCRA loophole that had left the word “immediately” undefined.
But, notably, Manchin proposed none of the things that Nixon and other vocal critics of the Institute plant really wanted: new limits on the storage and use of toxic chemicals, or additional enforcement aimed at ensuring plants operated safely and reduced pollution. The approach was in keeping with his more collaborative approach to government regulation. “Rather than going out with a ball bat and cease-and-desist orders and fines, I’d rather you spend the money to fix what’s wrong,” Manchin said during a speech to the West Virginia Coal Association in 2008.
Sitting at her desk in the Department of Environmental Protection, Nixon felt powerless. “Everyone has this perception that the agency is there to protect the public,” she said. “But I was seeing that it wasn’t. It was there to help the companies to continue to operate.”
The next decade brought a major victory but also new challenges for the people of Institute. Under pressure for its environmental record, Bayer closed its MIC unit. But soon after, political leaders joined with the owners of the Institute plant site to market the vacancy. US Methanol announced it was going to build in Institute so it could strip methanol, a building block for plastics and the chemical industry, from West Virginia’s growing supply of natural gas. Institute residents, now organized under the banner People Concerned About Chemical Safety, filed a legal challenge. But the state Air Quality Board rejected the group’s appeal. US Methanol moved forward with construction and said in a press release that it expected to open in the fourth quarter of 2021. The company did not respond to a request from ProPublica and Mountain State Spotlight seeking information about the current status of the project.
The activists also faced other challenges. After nearly three decades of campaigning in Institute, they were suffering from health problems. Warne Ferguson’s wife, Gail, had developed breathing problems and died a few months after the explosion, and he sued Bayer. But Bayer successfully argued he had filed those claims after the statute of limitations ran out. He himself died of cancer in 2014.
Nixon, who retired from the department of environmental protection in 2013, had several health issues over the years, some of which she attributed to her exposure in the 1985 leak. “My fingernails came off and my skin blistered and if I just rubbed my skin, it would come off, and I was like that all over,” she said. Nixon was treated for an autoimmune disease, given steroids and chemotherapy drugs, and she recovered. Dow, which is now Carbide’s parent company, did not respond to a request for comment.
In 2016, the EPA confirmed some of the community’s worst fears. The agency published a new analysis showing that one pollutant from the Institute plant, ethylene oxide, was more likely to cause cancer than previously thought. But it did not warn Institute or most of the other communities across the country who were facing the same risk. Only after an investigation by The Intercept and a critique from the agency’s Office of Inspector General did the EPA begin a more comprehensive outreach.
In West Virginia, the outreach was further delayed, in part because state regulators asserted that the EPA’s findings were based on outdated emissions estimates and inaccurate weather data. The state pushed the EPA for time to gather new emissions data from Carbide plants in Institute and South Charleston. Those results aren’t expected until at least June 2022, and the EPA says new ethylene oxide regulations won’t be released until at least 2024.
Contacted for this story, Manchin, a Democrat who was elected to the U.S. Senate in 2010 and has risen to become one of the most powerful voices in Washington, did not answer questions about whether he would urge the EPA to tighten toxic air emissions limits. A spokesperson said the senator supported infrastructure legislation, recently signed into law, that reinstated a chemical industry cleanup tax. The tax makes it “more costly for companies to produce and use certain chemicals like ethylene oxide.” Manchin, the spokesperson said, “continues to monitor the conditions in Institute.”
Nixon and other advocates have been pressing Manchin to support the Biden administration’s Build Back Better legislation, which would help communities like Institute, providing money for air-monitoring and pollution-reduction programs. The bill would also fund research initiatives at historically Black colleges, as well as workforce training and affordable housing resources. “We need these,” Nixon said at an October rally aimed at winning Manchin’s backing for the legislation. “These are not entitlements.”
But on Sunday, Manchin announced he would not support the bill, citing concerns about the national debt, rising inflation and spiking coronavirus cases. “My Democratic colleagues in Washington are determined to dramatically reshape our society in a way that leaves our country even more vulnerable to the threats we face,” he said in a statement.
Sen. Shelley Moore Capito, a Republican and the state’s other senator, also opposes the Build Back Better legislation, and fellow Republican Rep. Alex Mooney, who represents Institute in Congress, voted against it in the House. Neither responded to requests for comment for this story.
What’s clear, though, is that 96,000 people in the Charleston area are living in a toxic hot spot. According to ProPublica’s analysis, which examined far more chemicals than state and federal regulators and used five years’ worth of data, those living closest to Dow’s Institute plant are, over their lifetimes, being exposed to risk levels between 2 and 9 times as high as those the EPA considers acceptable. The analysis also found that ethylene oxide is the biggest contributor to excess industrial cancer risk from air pollutants nationwide.
EPA Administrator Michael S. Regan told ProPublica last month that the agency has consulted the news organization’s analysis and is “incorporating much of it into our revised and refined system so we can begin to address these issues” of industrial pollution and environmental inequities.
Speaking to Institute residents in September on Zoom, EPA’s top environmental justice official, Matthew Tejada, said the agency is “going to center our mission on achieving environmental justice because of the history of systemic and structural racism in this country that has placed communities of color, low-income communities and indigenous communities disproportionately in the path of harm.”
Promises to address environmental justice are not new though. In 1992, then-President George H.W. Bush created the Office of Environmental Equity, now known as the Office of Environmental Justice, at the EPA. In 1994, then-President Bill Clinton ordered all federal agencies to address disproportionate impacts of environmental hazards on minority and low-income people. On the 20th anniversary of that landmark order, then-President Barack Obama said his administration “is fighting to restore environments in our country’s hardest-hit places.” President Biden, too, has vowed to make racial and environmental equity a centerpiece of his administration, and the EPA now says it is taking steps to make environmental justice “part of our DNA.”
“There are super high expectations for this administration,” said Ali, the former EPA official. “People are no longer willing to wait — nor should they — for their communities to no longer be the dumping grounds or sacrifice zones.”
But those pledges from Washington have drawn criticism from officials in West Virginia, where regulators say the EPA is providing little guidance on how to apply the concept of environmental justice to actual enforcement and permitting actions. Indeed, just last month, the EPA Office of Inspector General cautioned that integrating these values into the agency’s many programs remains among the EPA’s “top management challenges.” Speaking to another community Zoom meeting in early December, Ed Maguire, the current holder of Nixon’s old environmental advocate position in the state Department of Environmental Protection, said, “On a lot of this stuff that becomes subjective, and when you’re in the regulatory business, subjectivity is not helpful. It’s got to be black and white.”
Asked whether the state Department of Environmental Protection has an environmental justice policy, he said no.
Listening from her home office, Nixon promptly corrected him. Such a policy was, in fact, approved in 2003, when she was the environmental advocate. It’s still posted on the agency’s website, she said. The policy states that the agency will “ensure that no segment of the population, because of its status as a low-income or minority community or any other factors relating to its racial or economic makeup, bear a disproportionate share of the risks and consequences of environmental pollution.”
But Nixon’s hard-fought efforts seem to exist on paper only: Terry Fletcher, a spokesperson for the department, told Mountain State Spotlight and ProPublica that the policy is no longer in effect because the state believes it has no authority under West Virginia law to make regulatory decisions “based on a community’s racial or economic makeup.”
After three and a half decades of advocacy, Nixon despairs that her old agency isn’t doing more. “Hopefully, they will actually use the data and come up with some better regulations,” she said. “We’ve been talking about environmental racism for a long time.”